HeartSciences Inc. (NASDAQ:HSCS) Short Interest Down 33.3% in August

HeartSciences Inc. (NASDAQ:HSCS) saw a large drop in short interest during the month of August. As of August 14th, there was short interest totaling 50,682 shares, a drop of 33.3% from the July 30th total of 76,030 shares. Based on an average daily volume of 66,843 shares, the short-interest ratio is presently 0.8 days. Currently, 1.4% of the shares of the company are sold short.

HeartSciences Stock Up 1.4%

HSCS traded up $0.04 during trading hours on Wednesday, hitting $3.16. The stock had a trading volume of 9,048 shares, compared to its average volume of 876,578. The stock has a market cap of $12.34 million, a PE ratio of -0.80 and a beta of 1.84. HeartSciences has a 1 year low of $1.63 and a 1 year high of $3.80. The company’s fifty day simple moving average is $2.54 and its 200 day simple moving average is $2.35.

HeartSciences (NASDAQ:HSCS) last posted its earnings results on Thursday, July 23rd. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.22). As a group, equities analysts expect that HeartSciences will post -3.04 EPS for the current year.

Hedge Funds Weigh In On HeartSciences

A hedge fund recently raised its stake in HeartSciences stock. Geode Capital Management LLC boosted its stake in HeartSciences Inc. (NASDAQ:HSCS) by 110.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,928 shares of the company’s stock after purchasing an additional 14,150 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of HeartSciences worth $83,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, HeartSciences has an average rating of “Hold” and a consensus target price of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.